Greystone managing director George Perros said that the chronic nature of diseases and conditions in these segments makes repetitive dosing necessary and thus the availability of therapies in safe and simple devices and packages remains an important element of patient acceptance.
As a group, specialty injectables will continue to grow on a unit dose basis during the forecast period, but at a lower rate as the market matures and prescription growth subsides.
Growth on a total revenue basis will be negatively impacted as patent expiry on several currently high-value-per-dose biologicals result in the introduction of competing brands and biosimilars, eroding prices and pressurising product margins.